Lannett Receives FDA Approval for Triamterene with Hydrochlorothiazide 37.5/25mg Capsules

Lannett Company, Inc.

today announced it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Triamterene with Hydrochlorothiazide 37.5/25mg Capsules. Triamterene with Hydrochlorothiazide 37.5/25mg Capsules is therapeutically equivalent to the reference listed drug, Dyazide^® Capsules, 25/37.5mg, of SmithKline Beecham. Sales of Triamterene Hydrochlorothiazide 37.5/25mg Capsules, at Average Wholesale Price were approximately $111 million for the 12 months ending October 2011, according to Wolters Kluwer.